{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:11:47Z","timestamp":1788505907933,"version":"build-2803163510"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Toxicol."],"abstract":"<jats:p>\n                    Comparative toxicology between synthetized and plant-derived cannabidiol (CBD) remains underexplored, as most previous research has focused on a single type of CBD. This leaves uncertainties regarding whether differences in origin, purity, or extraction methods affect the safety profiles or metabolic outcomes of CBD. This study assessed the\n                    <jats:italic>in vitro<\/jats:italic>\n                    safety,\n                    <jats:italic>in vitro<\/jats:italic>\n                    hepatotoxicity, and repeated oral dose pharmacokinetics (PK) of CBD in rats. Two brands of synthetized CBD were evaluated alongside two plant-derived CBD (a high-purity isolate and a lower-purity distillate) in vitro. These findings indicated no meaningful in vitro safety differences among the CBD sources and therefore supported selection of a single synthetized CBD source for an in vivo PK study in male Sprague-Dawley rats dosed orally once daily at 26.5 mg\/kg for 21 days. Blood samples were collected at multiple time points on days 1 and 21, and pre-dose samples on selected days to assess baseline accumulation. CBD and its metabolites (7-COOH-CBD, 7-OH-CBD, 6-OH-CBD) were measured in plasma and tissues using liquid chromatography-tandem mass spectrometry. All CBD samples showed comparable safety profiles, with no evidence of genotoxicity or mutagenicity in micronucleus and Ames assays, similar cytotoxicity in HepaRG monolayer cultures, and comparable cytochrome P450 (CYP) inhibition. Over 21 days, repeated dosing increased plasma CBD (AUC\n                    <jats:sub>INF<\/jats:sub>\n                    _D 567 vs. 209\u00a0h*kg*ng\/mL\/mg; Day 21 vs. 1), 7-COOH-CBD (AUC\n                    <jats:sub>last<\/jats:sub>\n                    _D 1006 vs. 581), 6-OH-CBD (AUC\n                    <jats:sub>last<\/jats:sub>\n                    _D 33 vs. 13) and 7-OH-CBD (AUC\n                    <jats:sub>last<\/jats:sub>\n                    _D 43 vs. 31) exposure, and prolonged CBD half-life (41.9\u00a0h vs. 5.9\u00a0h). The steady-state plasma CBD concentration was achieved by Day 6. Tissue analysis showed marked CBD accumulation in adipose tissue (70,124\u00a0ng\/g, 1470-fold relative to plasma level) and mesenteric lymph nodes (10,018\u00a0ng\/g, 201-fold relative to plasma level). Notably, 7-OH-CBD accumulated in adipose tissue (42\u00a0ng\/g, 21-fold relative to plasma level) and mesenteric lymph nodes (136\u00a0ng\/g, 73-fold relative to plasma level). Overall, high-purity synthetized and plant-derived CBD showed similar\n                    <jats:italic>in vitro<\/jats:italic>\n                    safety outcomes, while oral administration produced distinct accumulation of CBD and metabolites in plasma and tissue. These findings support flexible CBD source selection for standardized nonclinical research while highlighting the need to consider accumulation dynamics during repeated dosing.\n                  <\/jats:p>","DOI":"10.3389\/ftox.2026.1844643","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:11:50Z","timestamp":1788502310000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative in vitro safety assessments of synthetized and plant-derived cannabidiol (CBD), and pharmacokinetics of synthetized CBD: evidence of similar toxicological profiles and accumulation upon repeated oral administration"],"prefix":"10.3389","volume":"8","author":[{"given":"E. T.","family":"Wong","sequence":"first","affiliation":[{"name":"Verdeya Research Laboratories Pte. Ltd.","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bovard","sequence":"additional","affiliation":[{"name":"Verdeya Research Laboratories Pte. Ltd.","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. K.","family":"Schlage","sequence":"additional","affiliation":[{"name":"Consultant in Biology","place":["Bergisch Gladbach, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Xia","sequence":"additional","affiliation":[{"name":"Verdeya Research Laboratories Pte. Ltd.","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Isa","sequence":"additional","affiliation":[{"name":"Verdeya Research Laboratories Pte. Ltd.","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Sirbu","sequence":"additional","affiliation":[{"name":"Verdeya Research Laboratories Pte. Ltd.","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Kolli","sequence":"additional","affiliation":[{"name":"Philip Morris Products S.A.","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. N.","family":"Nikolajsen","sequence":"additional","affiliation":[{"name":"Fertin Pharma","place":["Vejle, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Fertin Pharma","place":["Vejle, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ho","sequence":"additional","affiliation":[{"name":"Verdeya Research Laboratories Pte. Ltd.","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Verdeya Research Laboratories Pte. Ltd.","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hoeng","sequence":"additional","affiliation":[{"name":"Verdeya SA, Cheseaux sur Lausanne","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","article-title":"ACNFP advice on the safety of synthetic cannabidiol (CBD)","year":"2025","journal-title":"Advisory Committee on Novel Foods and Processes"},{"key":"B2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40001-023-01443-6","article-title":"The synthetic cannabinoids menace: a review of health risks and toxicity","volume":"29","author":"Alzu'bi","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.dmd.2025.100037","article-title":"Cannabidiol and Delta9-tetrahydrocannabinol induce drug-metabolizing enzymes, but not transporters, in human hepatocytes: implications for predicting complex cannabinoid-drug interactions","volume":"53","author":"Balhara","year":"2025","journal-title":"Drug Metab. Dispos."},{"key":"B4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/jat\/bkab124","article-title":"Pharmacokinetic profile of \u03949-Tetrahydrocannabinol, cannabidiol and metabolites in blood following vaporization and oral ingestion of cannabidiol products","volume":"46","author":"Bergeria","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.3390\/molecules30132676","article-title":"Pharmacokinetics of cannabidiol in rat brain tissue after single-dose administration of different formulations","volume":"30","author":"Binova","year":"2025","journal-title":"Molecules"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.16093","article-title":"Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy","volume":"60","author":"Birnbaum","year":"2019","journal-title":"Epilepsia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"122651","DOI":"10.1016\/j.ijpharm.2023.122651","article-title":"Oral lipid-based formulations alter delivery of cannabidiol to different anatomical regions in the brain","volume":"635","author":"Brookes","year":"2023","journal-title":"Int. J. Pharm."},{"key":"B8","unstructured":"Cannabidiol (Epidiolex) non-clinical reviews\n          \n          \n          2018"},{"key":"B9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1021\/js960085v","article-title":"Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH","volume":"86","author":"Charman","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/26896583.2024.2366741","article-title":"Metabolism and liver toxicity of cannabidiol","volume":"42","author":"Chen","year":"2024","journal-title":"J. Environ. Sci. Health C Toxicol. Carcinog."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/nu14102101","article-title":"Cannabidiol (CBD) dosing: plasma pharmacokinetics and effects on accumulation in skeletal muscle, liver and adipose tissue","volume":"14","author":"Child","year":"2022","journal-title":"Nutrients"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/jat.4511","article-title":"An evaluation of the genotoxicity and 90-day repeated-dose toxicity of a CBD-rich hemp oil","volume":"43","author":"Clewell","year":"2023","journal-title":"J. Appl. Toxicol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1021\/acs.molpharmaceut.6b01118","article-title":"Analyzing the potential root causes of variability of pharmacokinetics in preclinical species","volume":"14","author":"Daublain","year":"2017","journal-title":"Mol. Pharm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3390\/ijms24021739","article-title":"Plasma-derived exosomes from NAFLD patients modulate the cannabinoid receptors' expression in cultured HepaRG cells","volume":"24","author":"De Nunzio","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"117218","DOI":"10.1016\/j.taap.2024.117218","article-title":"Safety assessment on CBD-rich hemp extract in sub-chronic cross-sex study with rats","volume":"495","author":"Dehner","year":"2025","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","article-title":"Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta(9)-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacol. Berl."},{"key":"B17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.toxrep.2020.02.014","article-title":"Safety assessment of a hemp extract using genotoxicity and oral repeat-dose toxicity studies in sprague-dawley rats","volume":"7","author":"Dziwenka","year":"2020","journal-title":"Toxicol. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e9708","DOI":"10.2903\/j.efsa.2025.9708","article-title":"Safety of synthetic cannabidiol as a novel food pursant to regulation (EU) 2015\/2283","volume":"23","year":"2025","journal-title":"EFSA J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.forsciint.2012.08.013","article-title":"Distribution of free and conjugated cannabinoids in human bile samples","volume":"223","author":"Fabritius","year":"2012","journal-title":"Forensic Sci. Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejpb.2021.02.013","article-title":"Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol","volume":"162","author":"Feng","year":"","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3390\/pharmaceutics13091349","article-title":"Inclusion of medium-chain triglyceride in lipid-based formulation of cannabidiol facilitates micellar solubilization in vitro,, but in vivo performance remains superior with pure sesame oil vehicle","volume":"13","author":"Feng","year":"","journal-title":"Pharmaceutics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"121947","DOI":"10.1016\/j.ijpharm.2022.121947","article-title":"Vegetable oils composition affects the intestinal lymphatic transport and systemic bioavailability of co-administered lipophilic drug cannabidiol","volume":"624","author":"Feng","year":"2022","journal-title":"Int. J. Pharm."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.chembiol.2025.10.005","article-title":"Rapid suppression of neuropathic pain and somatosensory hyperactivity by nano-formulated cannabidiol","volume":"32","author":"Feng","year":"2025","journal-title":"Cell Chem. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2023.1200269","article-title":"Cannabis: a multifaceted plant with endless potentials","volume":"14","author":"Fordjour","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"108442","DOI":"10.1016\/j.neuropharm.2020.108442","article-title":"Cannabidiol in the treatment for epilepsy: current evidence and perspectives for further research","volume":"185","author":"Franco","year":"2021","journal-title":"Neuropharmacology"},{"key":"B26","unstructured":"Cannabidiol Market (2026 - 2022)\n          \n          \n          2025"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2024.11.30.626177","DOI":"10.1101\/2024.11.30.626177","article-title":"Cannabidiol promotes apoptosis and downregulation of oncogenic factors","author":"Greenwood","year":"2024"},{"key":"B28","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1177\/0192623312448935","article-title":"Liver hypertrophy: a review of adaptive (adverse and non-adverse) changes -conclusions from the 3rd international ESTP expert workshop","volume":"40","author":"Hall","year":"2012","journal-title":"Toxicol. Pathol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"113778","DOI":"10.1016\/j.fct.2023.113778","article-title":"Oral toxicity evaluation of cannabidiol","volume":"176","author":"Henderson","year":"","journal-title":"Food Chem. Toxicol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"105425","DOI":"10.1016\/j.yrtph.2023.105425","article-title":"Genotoxicity evaluation of cannabidiol","volume":"142","author":"Henderson","year":"","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00406-024-01880-2","article-title":"Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits","volume":"275","author":"Hoch","year":"2025","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"B32","unstructured":"S2(R1) genotoxicity testing and data interpretation for pharmaceuticals intended for human use\n          \n          \n          2012"},{"key":"B33","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.1007\/s00210-024-03185-6","article-title":"Quantitative summary on the human pharmacokinetic properties of cannabidiol to accelerate scientific clinical application of cannabis","volume":"397","author":"Jang","year":"2024","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41419-019-2001-7","article-title":"Cannabidiol promotes apoptosis via regulation of XIAP\/smac in gastric cancer","volume":"10","author":"Jeong","year":"2019","journal-title":"Cell Death Dis."},{"key":"B35","volume-title":"Compositions and Methods for Treating Cancer","author":"Kogan","year":"2019"},{"key":"B36","doi-asserted-by":"publisher","first-page":"106058","DOI":"10.1016\/j.ejps.2021.106058","article-title":"Development and pharmacokinetic evaluation of a self-nanoemulsifying drug delivery system for the oral delivery of cannabidiol","volume":"168","author":"Kok","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00204-024-03826-y","article-title":"Genotoxicity of selected cannabinoids in human lymphoblastoid TK6 cells","volume":"98","author":"Kolar","year":"2024","journal-title":"Arch. Toxicol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3389\/fphar.2018.00889","article-title":"Cannabidiol (CBD) is a novel inhibitor for exosome and microvesicle (EMV) release in cancer","volume":"9","author":"Kosgodage","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"153469","DOI":"10.1016\/j.tox.2023.153469","article-title":"Establishment of a point of departure for CBD hepatotoxicity employing human HepaRG spheroids","volume":"488","author":"Li","year":"2023","journal-title":"Toxicology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/joim.13627","article-title":"Cannabidiol-associated hepatotoxicity: a systematic review and meta-analysis","volume":"293","author":"Lo","year":"2023","journal-title":"J. Intern Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"8143582","DOI":"10.1155\/2018\/8143582","article-title":"An assessment of the genotoxicity and subchronic toxicity of a supercritical fluid extract of the aerial parts of hemp","volume":"2018","author":"Marx","year":"2018","journal-title":"J. Toxicol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/ph13090219","article-title":"Towards better delivery of cannabidiol (CBD)","volume":"13","author":"Millar","year":"2020","journal-title":"Pharm. (Basel)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"571832","DOI":"10.3389\/fphar.2020.571832","article-title":"Cannabis contaminants limit pharmacological use of cannabidiol","volume":"11","author":"Montoya","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B45","first-page":"103","article-title":"Molecular targets of the phytocannabinoids: a complex picture","volume-title":"Progress in the Chemistry of Organic Natural Products","author":"Morales","year":"2017"},{"key":"B47","volume-title":"A Phase 1 Investigation into the Potential Effects of Cannabidiol on CYP3A4-mediated drug-drug Interactions in Healthy Volunteers","author":"Morrison","year":"2018"},{"key":"B48","volume-title":"National Advisory Committee for Laboratory Animal Research: Guidelines on the Care and Use of Animals for Scientific Purposes","year":"2022"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"B50","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/ph17020244","article-title":"Strategies to improve cannabidiol bioavailability and drug delivery","volume":"17","author":"O'Sullivan","year":"2024","journal-title":"Pharm. (Basel)"},{"key":"B51","volume-title":"Test No. 487:","year":"2016"},{"key":"B52","volume-title":"Test No. 471: Bacterial Reverse Mutation Test, OECD Guidelines for the Testing of Chemicals, Section 4","year":"2020"},{"key":"B53","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40263-020-00741-5","article-title":"Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications","volume":"34","author":"Perucca","year":"2020","journal-title":"CNS Drugs"},{"key":"B54","volume-title":"Cannabidiol (Ph. Eur. monograph 07\/2024:3151)","year":"2024"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.3390\/molecules26092774","article-title":"Cannabinoids, phenolics, terpenes and alkaloids of cannabis","volume":"26","author":"Radwan","year":"2021","journal-title":"Molecules"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1038\/s41598-025-87621-4","article-title":"A high-fat meal significantly impacts the bioavailability and biphasic absorption of cannabidiol (CBD) from a CBD-rich extract in men and women","volume":"15","author":"Saals","year":"2025","journal-title":"Sci. Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"114879","DOI":"10.1016\/j.colsurfb.2025.114879","article-title":"Oral formulations for cannabidiol: improved absolute oral bioavailability of biodegradable cannabidiol self-emulsifying drug delivery systems","volume":"255","author":"Sandmeier","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"B58","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1089\/can.2022.0121","article-title":"Pharmacokinetics of cannabidiol in sprague-dawley rats after oral and pulmonary administration","volume":"8","author":"Schwotzer","year":"2023","journal-title":"Cannabis Cannabinoid Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1089\/can.2023.0132","article-title":"Biological response after 14-Day cannabidiol and propylene glycol inhalation in sprague-dawley rats","volume":"10","author":"Schwotzer","year":"2025","journal-title":"Cannabis Cannabinoid Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3390\/ph17121644","article-title":"Research and clinical practice involving the use of cannabis products, with emphasis on cannabidiol: a narrative review","volume":"17","author":"Simei","year":"2024","journal-title":"Pharm. (Basel)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"100590","DOI":"10.1016\/j.mayocpiqo.2025.100590","article-title":"Medical Cannabis in the United States: comparing 2017 and 2024 State Qualifying Conditions to the 2017 National Academies of Sciences Report","volume":"9","author":"Stains","year":"2025","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"B62","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"B63","doi-asserted-by":"publisher","first-page":"105496","DOI":"10.1016\/j.yrtph.2023.105496","article-title":"Subchronic oral toxicity assessment of a cannabis extract","volume":"144","author":"Tallon","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/13880209.2025.2499075","article-title":"Genotoxic assessment of a Cannabis sativa L. extract","volume":"63","author":"Tallon","year":"2025","journal-title":"Pharm. Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, Double-blind, placebo-Controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e07322","DOI":"10.2903\/j.efsa.2022.7322","article-title":"Statement on safety of cannabidiol as a novel food: data gaps and uncertainties","volume":"20","author":"Turck","year":"2022","journal-title":"EFSA J."},{"key":"B66","unstructured":"Cannabis species inflorescence (USP HMC draft monograph)\n          \n          \n          2024"},{"key":"B67","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/0005-2736(76)90288-1","article-title":"The effect of short chain fatty acids on transmural electrical potential across rat small intestine in vivo","volume":"433","author":"Wall","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01480545.2025.2491544","article-title":"A 13-week oral toxicity and toxicokinetic study of cannabidiol in sprague Dawley rats with a 4-week recovery period","volume":"48","author":"Xia","year":"2025","journal-title":"Drug Chem. Toxicol."},{"key":"B69","first-page":"3448","article-title":"Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines","volume":"8","author":"Zgair","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"14542","DOI":"10.1038\/s41598-017-15026-z","article-title":"Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation","volume":"7","author":"Zgair","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Toxicology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftox.2026.1844643\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:11:53Z","timestamp":1788502313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftox.2026.1844643\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":70,"alternative-id":["10.3389\/ftox.2026.1844643"],"URL":"https:\/\/doi.org\/10.3389\/ftox.2026.1844643","relation":{},"ISSN":["2673-3080"],"issn-type":[{"value":"2673-3080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1844643"}}